Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung (Q84814743)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

Erb-b2 receptor tyrosine kinase 2

11 February 2020

main subject

1 reference

undifferentiated carcinoma

inferred from title

1 reference

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

12

Carsten Bokemeyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Tobias J Grob

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Ivonne Kannengiesser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Maria C Tsourlakis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Djordje Atanackovic

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Alexandra M Koenig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Yogesh K Vashist

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Hans Klose

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Andreas H Marx

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Susan Koops

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Jakob R Izbicki

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Guido Sauter

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Waldemar Wilczak

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

17 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1566-1573

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22899293%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/modpathol.2012.125

11 February 2020

exact match

0 references

cites work

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

The ErbB receptors and their ligands in cancer: an overview.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Antitumor activity of HER-2 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I nonsmall cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021

Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2012.125

7 January 2021